ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

418
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
08 Jan 2024 09:00

Hong Kong Connect Flows (December): Six Months of Inflows

We analyzed the Hong Kong Connect Scheme for December and highlight flows for Meituan, CNOOC, PICC P&C, China Mobile, Tencent, Xiaomi, HKEx, Wuxi...

Logo
325 Views
Share
05 Jan 2024 10:43

Hong Kong Buybacks Weekly (Jan 5th): Tencent, AIA, Xiaomi

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
759 Views
Share
bullishChina Mobile
30 Dec 2023 14:44

HK Connect SOUTHBOUND Flows (To 29Dec23); CNOOC & Telcos to the BUY Side, Tracker Fund Sold Bigly

HK Connect SOUTHBOUND Flows this week were light on a shortened 3-day week. High-div SOEs like Energy names and the large telcos were significantly...

Logo
404 Views
Share
29 Dec 2023 09:33

Hong Kong Buybacks Weekly (Dec 22nd): Tencent, AIA, Li Ning

​We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
548 Views
Share
x